GUILFORD, Conn., May 19 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the relocation of the company from Guilford, Connecticut, to Lexington, Massachusetts. RainDance said it will open the new facility and start up commercial and manufacturing operations effective May 27, 2008.
"With the launch of our first life sciences application scheduled for the fourth quarter of this year, it's important for RainDance to be located in the nation's preeminent biotechnology center," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "As we enter the commercial phase of product development and begin manufacturing operations, a larger facility and access to the exceptional life sciences talent pool and customer base of the greater Boston/Cambridge area will be essential."
The company said it will employ approximately 65 people at the Lexington facility by the end of the year. "During the coming months, we will be hiring about 30 people, including biologists and chemists, mechanical engineers and technicians, software programmers, customer service representatives, and administrative support," said McNary.
RainDance's new 28,000-square-foot building in Lexington, located at 44 Hartwell Avenue, more than doubles the space of its present Guilford, Connecticut, facility. The building will house the firm's executive and administrative offices, research and development group, sales and marketing team, and manufacturing operations. In addition, the company plans to purchase more than $500,000 in scientific and office equipment.
"This move locates RainDance in a community of scientific investigators
and laboratories that is closely aligned with our business and technology,"
Effective May 27, 2008, RainDance Technologies' new contact information will be as follows:
44 Hartwell Avenue
Lexington, MA 02421-3103
Phone -- 781-861-6300
Fax -- 781-861-1233
About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.
The company's technology produces picoliter-sized droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. The droplets are processed on a small chip that has no moving parts or valves. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.
RainDance's initial application will focus on the targeted resequencing of the human genome -- one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
RainDance was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter.
For more information, please visit http://www.raindancetechnologies.com.
|SOURCE RainDance Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved